Recent advances in dermatomyositis-specific autoantibodies

Current Opinion in Rheumatology

Volumn 28, Issue 6, 2016, Pages 636-644

  Fujimoto, Manabu ^a   Watanabe, Rei ^a   Ishitsuka, Yosuke ^a   Okiyama, Naoko ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Anti melanoma differentiation antigen 5 antibodies; Anti nuclear matrix protein 2 antibodies; Anti small ubiquitin like modifier activating enzyme antibodies; Anti transcriptional intermediary factor 1 antibodies

Indexed keywords

AUTOANTIBODY; JO 1 ANTIBODY; MELANOMA DIFFERENTIATION ANTIGEN 5 ANTIBODY; NUCLEAR MATRIX PROTEIN 2 ANTIBODY; SMALL UBIQUITIN LIKE MODIFIER ACTIVATING ENZYME ANTIBODY; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1 ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DNA BINDING PROTEIN; IFIH1 PROTEIN, HUMAN; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; NUCLEAR MATRIX PROTEIN 2; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1; UBIQUITIN PROTEIN LIGASE;

ANTIBODY DETECTION; DERMATOMYOSITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MUSCLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; CALCINOSIS; DISEASE COURSE; IMMUNOLOGY; INTERSTITIAL LUNG DISEASE; MUSCLE WEAKNESS; NEOPLASM; PROGNOSIS;

AUTOANTIBODIES; BIOMARKERS; CALCINOSIS; DERMATOMYOSITIS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; HUMANS; INTERFERON-INDUCED HELICASE, IFIH1; LUNG DISEASES, INTERSTITIAL; MUSCLE WEAKNESS; NEOPLASMS; NUCLEAR PROTEINS; PROGNOSIS; TRANSCRIPTION FACTORS; UBIQUITIN-ACTIVATING ENZYMES;

EID: 84983071807     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000329     Document Type: Review

References (52)

1. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2015; 280:8-23.
2. Satoh M, Tanaka S, Ceribelli A, et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol 2015; doi: 10.1007/s12016-015-8510-y. [Epub ahead of print]
3. Gunawardena H. The clinical features of myositis-associated autoantibodies: a review. Clin Rev Allergy Immunol 2015; doi: 10.1007/s12016-015-8513-8. [Epub ahead of print]
4. Tansley S, Gunawardena H. The evolving spectrum of polymyositis and dermatomyositis-moving towards clinicoserological syndromes: a critical review. Clin Rev Allergy Immunol 2014; 47:264-273.
5. Fujimoto M. Dermatomyositis: myositis-specific autoantibodies and skin manifestations. Clin Exp Neuroimmunol 2012; 3:74-84.
6. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kD polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52:1571-1576.
7. Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60:2193-2200.
8. Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 2010; 49:433-440.
9. Chen Z, Cao M, Plana MN, et al. Utility of antimelanoma differentiation-associated gene 5 antibody measurement in identifying patients with derma-tomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken) 2013; 65:1316-1324.
10. Zhang L, Wu G, Gao D, et al. Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. PLoS One 2016; 11:e0155381.
11. Chen Z, Hu W, Wang Y, et al. Distinct profiles of myositis-specific auto-antibodies in Chinese and Japanese patients with polymyositis/dermatomyo-sitis. Clin Rheumatol 2015; 34:1627-1631.
12. Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65:25-34.
13. Hall JC, Casciola-Rosen L, Samedy LA, et al. Antimelanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) 2013; 65:1307-1315.
14. Moghadam-Kia S, Oddis CV, Sato S, et al. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken) 2016; 68:689-694.
15. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, et al. Anti-TIF1gam-ma antibodies (antip155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Ann Rheum Dis 2012; 71:993-996.
16. Ceribelli A, Fredi M, Taraborelli M, et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyo-sitis. Clin Exp Rheumatol 2014; 32:891-897.
17. Bodoki L, Nagy-Vincze M, Griger Z, et al. Four dermatomyositis-specific autoantibodies-anti-TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 2014; 13:1211-1219.
18. Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with derma-tomyositis-specific autoantibodies in adult Japanese patients with dermato-myositis: a multicenter cross-sectional study. Arch Dermatol 2011; 147:391-398.
19. Narang NS, Casciola-Rosen L, Li S, et al. Cutaneous ulceration in dermato-myositis: association with antimelanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res (Hoboken) 2015; 67:667-672.
20. Kobayashi N, Takezaki S, Kobayashi I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford) 2015; 54:784-791.
21. Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 2014; 16:R138.
22. Takada T, Aoki A, Asakawa K, et al. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis. Respir Med 2015; 109:1174-1180.
23. Sato S, Murakami A, Kuwajima A, et al. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One 2016; 11:e0154285.
24. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kDa protein is associated with dermatomyositis. Arthritis Rheum 2006; 54:3682-3689.
25. Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermato-myositis: an association with malignancy. Rheumatology (Oxford) 2007; 46:25-28.
26. Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti155/140 auto-antibodies target transcriptional intermediary factor 1 family proteins. Arthritis Rheum 2012; 64:513-522.
27. Rider LG, Shah M, Mamyrova G, et al. Childhood Myositis Heterogeneity Collaborative Study G. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013; 92:223-243.
28. Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: patho-genesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med 2016; 280:24-38.
29. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyo-sitis. Rheumatology (Oxford) 2008; 47:324-328.
30. Habers GE, Huber AM, Mamyrova G, et al. Association of myositis autoantibodies, clinical features, and environmental exposures at illness onset with disease course in juvenile myositis. Arthritis Rheumatol 2016; 68: 761-768.
31. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O'Callaghan A, et al. Usefulness of antip155 autoantibody for diagnosing cancer-associated dermato-myositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64:523-532.
32. Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis. J Am Acad Dermatol 2015; 72:449-455.
33. Mugii N, Hasegawa M, Matsushita T, et al. Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies. PLoS One 2016; 11:e0154746.
34. Oddis CV, Fertig N, Goel A, et al. Clinical and serological characterization of the anti-MJ antibody in childhood myositis [abstract]. Arthritis Rheum 1997; 40:S139.
35. Targoff IN, Trieu EP, Levy-Neto M, et al. Sera with autoantibodies to the MJ antigen react with NXP2 [abstract]. Arthritis Rheum 2007; 56:S787.
36. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009; 36:2547-2551.
37. Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60:1807-1814.
38. Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile derma-tomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford) 2014; 53:2204-2208.
39. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012; 71:710-713.
40. Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 2013; 65:2954-2962.
41. Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D. Identification of clinical features and autoantibodies associated with calcinosis in dermato-myositis. JAMA Dermatol 2014; 150:724-729.
42. Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoanti-gen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 2009; 68:1621-1625.
43. Fujimoto M, Matsushita T, Hamaguchi Y, et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with derma-tomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis 2013; 72:151-153.
44. Muro Y, Sugiura K, Akiyama M. Low prevalence of antismall ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoim-munity 2013; 46:279-284.
45. Tarricone E, Ghirardello A, Rampudda M, et al. Anti-SAE antibodies in autoimmune myositis: Identification by unlabelled protein immunoprecipi-tation in an Italian patient cohort. J Immunol Methods 2012; 384: 128-134.
46. Tampoia M, Notarnicola A, Abbracciavento L, et al. A new immunodot assay for multiplex detection of autoantibodies in a cohort of Italian patients with idiopathic inflammatory myopathies. J Clin Lab Anal 2016; doi: 10.1002/jcla.21948. [Epub ahead of print]
47. Muro Y, Sugiura K, Nara M, et al. High incidence of cancer in antismall ubiquitin-like modifier activating enzyme antibody-positive dermatomyositis. Rheumatology (Oxford) 2015; 54:1745-1747.
48. Albrecht I, Wick C, Hallgren A, et al. Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest 2015; 125:4612-4624.
49. Mescam-Mancini L, Allenbach Y, Hervier B, et al. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 2015; 138:2485-2492.
50. Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, et al. The prevalence of individual histopathologic features varies according to autoanti-body status in muscle biopsies from patients with dermatomyositis. J Rheumatol 2015; 42:1448-1454.
51. Allenbach Y, Leroux G, Suarez-Calvet X, et al. Dermatomyositis with or without anti-melanoma differentiation-associated gene 5antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol 2016; 186:691-700.
52. Deakin CT, Yasin SA, Simou S, et al. Muscle biopsy in combination with myositis-specific autoantibodies aids prediction ofoutcomes in juvenile dermatomyositis. Arthritis Rheumatol 2016; doi: 10.1002/art.39753. [Epub ahead of print]